| Similar Articles |
|---|
 |
The Motley Fool
October 14, 2008
Brian Orelli |
Johnson & Johnson, Heal Thyself When your brother falls, you've got to pick up the pace.   |
The Motley Fool
January 20, 2009
Brian Orelli |
Johnson & Johnson Nimble ... for Now The health-care giant reports increasing earnings, despite falling revenue. |
The Motley Fool
October 17, 2007
Brian Orelli |
J&J Puts Band-Aid on the Quarter Investors, Johnson & Johnson's earnings report reads like a one-hit wonder's second album. It goes from good to bad in the blink of an eye -- or in this case, a paragraph or so. |
The Motley Fool
January 23, 2008
Brian Orelli |
A Dose of Stability From J&J Top-line growth looked great at Johnson & Johnson -- more than 16% year over year -- but when you dove a little further into the earnings, growth wasn't quite that stellar. |
The Motley Fool
July 16, 2008
Brian Orelli |
J&J's Lesson to Investors: Diversify! Johnson & Johnson's second-quarter earnings report gives investors an object lesson of the benefits of the principle of diversification. |
The Motley Fool
November 13, 2007
Brian Orelli |
Another Punch in the Nose for Pfizer The FDA clears ZYRTEC-D for over-the-counter sales; marketing of the medication will now switch hands from Pfizer to Johnson & Johnson. Investors, take note. |
The Motley Fool
January 2, 2008
Brian Orelli |
Congestion in the OTC Market J&J already has generic competition for its new drug Zyrtec. |
The Motley Fool
July 17, 2007
Ryan Fuhrmann |
Diagnosing J&J's Product Diversity Health-care giant Johnson & Johnson's blues may indicate trouble ahead for competitors. Investors, take note. |
The Motley Fool
January 20, 2004
Alyce Lomax |
Is J&J Pain-Free? Fourth-quarter revenues surge, but rivals are waiting in the wings. |
The Motley Fool
July 24, 2009
Brian Orelli |
Pfizer's Bride Puts on the Makeup Pfizer may not be getting a powerhouse revenue driver in Wyeth, but at least its bride knows how to make the bottom line look pretty. |
The Motley Fool
December 31, 2007
Brian Orelli |
Best Stock for 2008: Johnson & Johnson Down on its luck for 2007, here's why Johnson & Johnson's stock will rebound in 2008. |
The Motley Fool
January 26, 2005
Rich Smith |
J&J: Dialing for Dollars It pays to be big in a weak dollar world. Just ask Johnson & Johnson. Still, in the year to come, investors will want to keep one eye on J&J's operational performance, and the other on the U.S. Dollar's exchange rates against foreign currencies. |
The Motley Fool
July 14, 2008
Brian Orelli |
Foolish Forecast: J&J Trudges Along In advance of earnings analysts wonder if Johnson & Johnson is a recovery story waiting to happen, or still stuck in a rut? |
The Motley Fool
October 12, 2004
Alyce Lomax |
Take It Away, J&J Should investors sweat a coming slowdown in growth for pharmaceutical and consumer products giant Johnson & Johnson? |
The Motley Fool
September 25, 2009
Brian Orelli |
Oh, No! Another Tylenol Recall? Take a deep breath. Everything will be OK. |
The Motley Fool
June 27, 2008
Ryan Fuhrmann |
Recession-Proof Stocks: Johnson & Johnson This industry titan's stock is beaten down and should recover quite nicely when headwinds stop working against it and start to shift toward its back. |
BusinessWeek
June 18, 2007
Arlene Weintraub |
Johnson & Johnson's Next Baby? J&J could use an infusion of new drugs and devices from an acquisition such as Boston Scientific. |
The Motley Fool
April 15, 2009
Brian Orelli |
Johnson & Johnson Still Withstands Recession While Johnson & Johnson is big, it has proven to be agile during the recession, and this quarter was no different. |
The Motley Fool
October 12, 2007
Ryan Fuhrmann |
Dueling Fools: Johnson & Johnson Bull The bullish opinion on J&J is that the company is handling current difficulties well, and the low stock price makes for a bargain for investors. |
The Motley Fool
September 27, 2010
Brian Orelli |
This Recall Is Different -- In a Good Way Johnson & Johnson strikes again, but it's not so bad this time. |
The Motley Fool
July 15, 2009
Brian Orelli |
Less Inflammation From Abbott's Quarter Humira is headed back in the right direction. |
The Motley Fool
July 17, 2008
Brian Orelli |
Investors Yawn at Abbott Labs' Growth Abbott Labs may be firing on all cylinders, but investors were less than impressed with its earnings release |
The Motley Fool
October 19, 2011
Brian Orelli |
Not the Best Quarter, but... There's little reason to worry about Johnson & Johnson. |
The Motley Fool
April 27, 2009
Brian Orelli |
Johnson & Johnson's Simponi Sticks to the Wall Johnson & Johnson gets its second-generation TNF-alpha inhibitor past the FDA. |
The Motley Fool
July 14, 2009
Brian Orelli |
J&J Eats a Hard Quarter Tough year-over-year comparisons are no match for the health care giant. |
The Motley Fool
July 13, 2004
Jeff Hwang |
J&J Weathers Stent Duel The medical device and diagnostics business Johnson & Johnson delivers a solid second quarter despite competition from Boston Scientific's Taxus stent. |
The Motley Fool
October 12, 2007
Billy Fisher |
Dueling Fools: Johnson & Johnson Bear Rebuttal The bears say that J&J is a good company, but will underperform looking forward. |
The Motley Fool
April 13, 2004
Alyce Lomax |
J&J Makes the Day It may be over a hundred years old, but the company reports a spry first quarter. |
The Motley Fool
June 30, 2009
Brian Orelli |
Johnson & Johnson Inflames Abbott $1.67 billion is one hefty reward. |
The Motley Fool
November 22, 2006
Brian Lawler |
Dueling Fools: Johnson & Johnson Bear Rebuttal The bottom line is that investors are putting their faith in the ability of J&J's management to acquire its way to renewing top-line growth in the coming years. |
The Motley Fool
July 28, 2011
Melly Alazraki |
J&J or Novartis? Novartis' businesses are an investor's delight; J&J's improving but isn't there yet. |
The Motley Fool
June 12, 2008
Brian Orelli |
Schering-Plough and J&J Score a Triple-Triple Schering-Plough and Johnson & Johnson present three phase 3 trials for a single drug, their anti-TNF medication golimumab. |
The Motley Fool
October 19, 2010
Brian Orelli |
Watch a 40% Decline Disappear The greatest thing going for Johnson & Johnson is its diversity in product offerings. |
The Motley Fool
April 19, 2005
Nathan Slaughter |
Diagnosis: JNJ A-OK The health-care conglomerate beats expectations on strong international results. |
The Motley Fool
April 22, 2010
Brian Orelli |
Abbott's Stuck in a Double-Digit Rut The company keeps cranking out solid earnings, but investors don't seem to care. |
The Motley Fool
December 6, 2007
Brian Orelli |
An Unlikely Chat With Your Doctor J&J starts direct-to-consumer advertising of its drug-eluting stent. Can it really pay off? |
The Motley Fool
October 7, 2010
Anand Chokkavelu |
How Johnson & Johnson Really Makes Money Hint: It's not Tylenol. |
The Motley Fool
January 27, 2010
Brian Orelli |
Humira or Not, Abbott's on a Roll Investors worry about how Abbott's Humira is such a large fraction of the company's revenue, and then when the company turns in a nice quarter even without strong U.S. sales of Humira, they complain about that. |
The Motley Fool
October 13, 2009
Brian Orelli |
J&J Needs to Get Drugged Up Medical devices and diagnostics pass by drugs as the main revenue source. |
BusinessWeek
January 30, 2006
Robert Barker |
Guidant Or No, J&J Is A Buy To Wall Street, Johnson & Johnson has been sounding like Dumb & Dumber. |
The Motley Fool
June 26, 2006
Stephen D. Simpson |
J&J Makes an Expensive Deal J&J announced that it has reached an agreement with Pfizer to acquire the latter's consumer health-care business for $16.6 billion in cash. Consumer health is a fine business line, but is it worth this much money? Investors, take note. |
The Motley Fool
January 28, 2011
Anand Chokkavelu |
10 Core Stocks: A Johnson & Johnson Update The steady reliability of J&J stock will comfort the core of your portfolio when the market gets a boo-boo. |
The Motley Fool
November 26, 2007
Brian Orelli |
Johnson & Johnson Reorganizes -- Who Wins? Johnson & Johnson announces the second phase of its reorganization plan. While it may take years to see whether the measures will help J&J, some other companies could benefit far more quickly. |
The Motley Fool
October 2, 2008
Brian Orelli |
Will Johnson & Johnson Ever Get Its Money? For investors, there are a couple of lessons here. First, perhaps more than any other, the health care sector has a lot of lawsuits. |
The Motley Fool
May 20, 2011
Andrea Kalvesmaki |
Johnson & Johnson's Billion-Dollar Move Orthopedics are the name of the game for this company's future earnings. |
The Motley Fool
June 4, 2010
Brian Orelli |
Out With Drugs, in With Medical Devices Johnson & Johnson's movement in medical devices and diagnostics is headed in the right direction, but whether Johnson & Johnson is a buy depends a lot on how it handles its current drug problem. Unfortunately investors can't have one without the other. |
The Motley Fool
January 24, 2006
Stephen D. Simpson |
Shake a Leg, J&J! J&J isn't a perfect story, but investors who buy today and hold for a while will be happy they did. |
The Motley Fool
February 24, 2004
Alyce Lomax |
J&J, Guidant Join Forces With intense rivalry looming, is a competitive partnership in vain? |
The Motley Fool
July 19, 2011
Brian Orelli |
J&J: Better, but Not Best A decent-looking quarter, but a turnaround could still take awhile. |
The Motley Fool
September 24, 2010
Anand Chokkavelu |
10 Core Stocks for Your Portfolio: Johnson & Johnson The health care behemoth makes the list |
